RETRACTED ARTICLE: Chronic and progressive dopaminergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and free fatty acids, the role of interlokin-1 beta

Human studies indicate that Parkinson’s disease (PD) associates with disruption in metabolism of glucose and free fatty acids (FFA). Studies have shown that interlukin-1beta (IL-1β) causes hypoglycemia through insulin- independent mechanisms. Here, we investigated association between dopaminergic ne...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Metabolic brain disease 2022-02, Vol.37 (2), p.373-381
Hauptverfasser: Sarbazi-Golezari, Ali, Haghdoost-Yazdi, Hashem
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 381
container_issue 2
container_start_page 373
container_title Metabolic brain disease
container_volume 37
creator Sarbazi-Golezari, Ali
Haghdoost-Yazdi, Hashem
description Human studies indicate that Parkinson’s disease (PD) associates with disruption in metabolism of glucose and free fatty acids (FFA). Studies have shown that interlukin-1beta (IL-1β) causes hypoglycemia through insulin- independent mechanisms. Here, we investigated association between dopaminergic neuronal death, as the main pathophysiological mechanism underlying PD, and serum levels of glucose, FFA and IL-1β in 6-hydroxydopamine (6-OHDA) animal model of PD. Neurotoxin of 6-OHDA was injected into medial forebrain bundle and multiple behavioral testes were carried out during eight weeks thereafter. Blood was collected before the toxin and in second and eight weeks thereafter. Then, brain of the animals was perfused to assess survival of dopaminergic (DAergic) neurons in substantia nigra by tyrosine hydroxylase (TH) immunohistochemistry. Glucose, FFA and IL-1β levels were determined using calorimetric method and specific ELISA kits. In compare to control, 6-OHDA- treated rats had less glucose and FFA levels in the eight week and higher IL-1β level in the both second and eight weeks. Based on severity of behavioral symptoms, 6-OHDA- treated rats were divided into two subgroups of severe and mild. Number of TH- positive cells in these subgroups was 83 and 45% less than that in control. Also, both subgroups showed less weight gain, lower glucose and FFA and higher IL-1β in eight week. Our data indicate that moderate to severe progressive DAergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and FFA. Increase in IL-1β production following neuronal death possibly mediated this decrease.
doi_str_mv 10.1007/s11011-021-00868-4
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2622096471</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2622096471</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1644-a248b1c17ff6643489383e598efbb4bb17340a74756102615a4a4addf9355fdc3</originalsourceid><addsrcrecordid>eNp9kc-KE0EQxgdRMK6-gKcCr452T_f88xZi1IWAEOJ5qJmpnvQ66Y5dPbvs-_lgdjaCNymKOny_rwrqy7K3UnyQQtQfWUohZS6K1KKpmlw_y1ayrFVeq6p8nq1E05R5rVvxMnvFfCeEUKVsV9nv_fawX28O28-w3h9uN7vtJ9gcg3d2AHQjnIOfAjHbe4LRn_FkHYUpiY6WROEMI2E8gnXAS88RXbQIzk4BAZn9YDESw4NNDCZ2CIRMTziF5QQz3dPM4A1M8zL4JF2umkAEBmN8BBzsyO8hHgmCn-lCWhcpzP6ndbmEniK-zl4YnJne_J032Y8v28PmW777_vV2s97lg6y0zrHQTS8HWRtTVVrpplWNorJtyPS97ntZKy2w1nVZSVFUskSdahxNq8rSjIO6yd5d96av_FqIY3fnl5CewF1RFYVoK13LRBVXagieOZDpzsGeMDx2UnSXtLprWl1Kq3tKq9PJpK4mTrCbKPxb_R_XH4p5mUc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2622096471</pqid></control><display><type>article</type><title>RETRACTED ARTICLE: Chronic and progressive dopaminergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and free fatty acids, the role of interlokin-1 beta</title><source>Springer Nature - Complete Springer Journals</source><creator>Sarbazi-Golezari, Ali ; Haghdoost-Yazdi, Hashem</creator><creatorcontrib>Sarbazi-Golezari, Ali ; Haghdoost-Yazdi, Hashem</creatorcontrib><description>Human studies indicate that Parkinson’s disease (PD) associates with disruption in metabolism of glucose and free fatty acids (FFA). Studies have shown that interlukin-1beta (IL-1β) causes hypoglycemia through insulin- independent mechanisms. Here, we investigated association between dopaminergic neuronal death, as the main pathophysiological mechanism underlying PD, and serum levels of glucose, FFA and IL-1β in 6-hydroxydopamine (6-OHDA) animal model of PD. Neurotoxin of 6-OHDA was injected into medial forebrain bundle and multiple behavioral testes were carried out during eight weeks thereafter. Blood was collected before the toxin and in second and eight weeks thereafter. Then, brain of the animals was perfused to assess survival of dopaminergic (DAergic) neurons in substantia nigra by tyrosine hydroxylase (TH) immunohistochemistry. Glucose, FFA and IL-1β levels were determined using calorimetric method and specific ELISA kits. In compare to control, 6-OHDA- treated rats had less glucose and FFA levels in the eight week and higher IL-1β level in the both second and eight weeks. Based on severity of behavioral symptoms, 6-OHDA- treated rats were divided into two subgroups of severe and mild. Number of TH- positive cells in these subgroups was 83 and 45% less than that in control. Also, both subgroups showed less weight gain, lower glucose and FFA and higher IL-1β in eight week. Our data indicate that moderate to severe progressive DAergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and FFA. Increase in IL-1β production following neuronal death possibly mediated this decrease.</description><identifier>ISSN: 0885-7490</identifier><identifier>EISSN: 1573-7365</identifier><identifier>DOI: 10.1007/s11011-021-00868-4</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biochemistry ; Biomedical and Life Sciences ; Biomedicine ; Metabolic Diseases ; Neurology ; Neurosciences ; Oncology ; Original Article</subject><ispartof>Metabolic brain disease, 2022-02, Vol.37 (2), p.373-381</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1644-a248b1c17ff6643489383e598efbb4bb17340a74756102615a4a4addf9355fdc3</citedby><cites>FETCH-LOGICAL-c1644-a248b1c17ff6643489383e598efbb4bb17340a74756102615a4a4addf9355fdc3</cites><orcidid>0000-0001-5825-8758</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11011-021-00868-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11011-021-00868-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids></links><search><creatorcontrib>Sarbazi-Golezari, Ali</creatorcontrib><creatorcontrib>Haghdoost-Yazdi, Hashem</creatorcontrib><title>RETRACTED ARTICLE: Chronic and progressive dopaminergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and free fatty acids, the role of interlokin-1 beta</title><title>Metabolic brain disease</title><addtitle>Metab Brain Dis</addtitle><description>Human studies indicate that Parkinson’s disease (PD) associates with disruption in metabolism of glucose and free fatty acids (FFA). Studies have shown that interlukin-1beta (IL-1β) causes hypoglycemia through insulin- independent mechanisms. Here, we investigated association between dopaminergic neuronal death, as the main pathophysiological mechanism underlying PD, and serum levels of glucose, FFA and IL-1β in 6-hydroxydopamine (6-OHDA) animal model of PD. Neurotoxin of 6-OHDA was injected into medial forebrain bundle and multiple behavioral testes were carried out during eight weeks thereafter. Blood was collected before the toxin and in second and eight weeks thereafter. Then, brain of the animals was perfused to assess survival of dopaminergic (DAergic) neurons in substantia nigra by tyrosine hydroxylase (TH) immunohistochemistry. Glucose, FFA and IL-1β levels were determined using calorimetric method and specific ELISA kits. In compare to control, 6-OHDA- treated rats had less glucose and FFA levels in the eight week and higher IL-1β level in the both second and eight weeks. Based on severity of behavioral symptoms, 6-OHDA- treated rats were divided into two subgroups of severe and mild. Number of TH- positive cells in these subgroups was 83 and 45% less than that in control. Also, both subgroups showed less weight gain, lower glucose and FFA and higher IL-1β in eight week. Our data indicate that moderate to severe progressive DAergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and FFA. Increase in IL-1β production following neuronal death possibly mediated this decrease.</description><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Metabolic Diseases</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Oncology</subject><subject>Original Article</subject><issn>0885-7490</issn><issn>1573-7365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kc-KE0EQxgdRMK6-gKcCr452T_f88xZi1IWAEOJ5qJmpnvQ66Y5dPbvs-_lgdjaCNymKOny_rwrqy7K3UnyQQtQfWUohZS6K1KKpmlw_y1ayrFVeq6p8nq1E05R5rVvxMnvFfCeEUKVsV9nv_fawX28O28-w3h9uN7vtJ9gcg3d2AHQjnIOfAjHbe4LRn_FkHYUpiY6WROEMI2E8gnXAS88RXbQIzk4BAZn9YDESw4NNDCZ2CIRMTziF5QQz3dPM4A1M8zL4JF2umkAEBmN8BBzsyO8hHgmCn-lCWhcpzP6ndbmEniK-zl4YnJne_J032Y8v28PmW777_vV2s97lg6y0zrHQTS8HWRtTVVrpplWNorJtyPS97ntZKy2w1nVZSVFUskSdahxNq8rSjIO6yd5d96av_FqIY3fnl5CewF1RFYVoK13LRBVXagieOZDpzsGeMDx2UnSXtLprWl1Kq3tKq9PJpK4mTrCbKPxb_R_XH4p5mUc</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>Sarbazi-Golezari, Ali</creator><creator>Haghdoost-Yazdi, Hashem</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><orcidid>https://orcid.org/0000-0001-5825-8758</orcidid></search><sort><creationdate>20220201</creationdate><title>RETRACTED ARTICLE: Chronic and progressive dopaminergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and free fatty acids, the role of interlokin-1 beta</title><author>Sarbazi-Golezari, Ali ; Haghdoost-Yazdi, Hashem</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1644-a248b1c17ff6643489383e598efbb4bb17340a74756102615a4a4addf9355fdc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Metabolic Diseases</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Oncology</topic><topic>Original Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sarbazi-Golezari, Ali</creatorcontrib><creatorcontrib>Haghdoost-Yazdi, Hashem</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Metabolic brain disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sarbazi-Golezari, Ali</au><au>Haghdoost-Yazdi, Hashem</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>RETRACTED ARTICLE: Chronic and progressive dopaminergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and free fatty acids, the role of interlokin-1 beta</atitle><jtitle>Metabolic brain disease</jtitle><stitle>Metab Brain Dis</stitle><date>2022-02-01</date><risdate>2022</risdate><volume>37</volume><issue>2</issue><spage>373</spage><epage>381</epage><pages>373-381</pages><issn>0885-7490</issn><eissn>1573-7365</eissn><abstract>Human studies indicate that Parkinson’s disease (PD) associates with disruption in metabolism of glucose and free fatty acids (FFA). Studies have shown that interlukin-1beta (IL-1β) causes hypoglycemia through insulin- independent mechanisms. Here, we investigated association between dopaminergic neuronal death, as the main pathophysiological mechanism underlying PD, and serum levels of glucose, FFA and IL-1β in 6-hydroxydopamine (6-OHDA) animal model of PD. Neurotoxin of 6-OHDA was injected into medial forebrain bundle and multiple behavioral testes were carried out during eight weeks thereafter. Blood was collected before the toxin and in second and eight weeks thereafter. Then, brain of the animals was perfused to assess survival of dopaminergic (DAergic) neurons in substantia nigra by tyrosine hydroxylase (TH) immunohistochemistry. Glucose, FFA and IL-1β levels were determined using calorimetric method and specific ELISA kits. In compare to control, 6-OHDA- treated rats had less glucose and FFA levels in the eight week and higher IL-1β level in the both second and eight weeks. Based on severity of behavioral symptoms, 6-OHDA- treated rats were divided into two subgroups of severe and mild. Number of TH- positive cells in these subgroups was 83 and 45% less than that in control. Also, both subgroups showed less weight gain, lower glucose and FFA and higher IL-1β in eight week. Our data indicate that moderate to severe progressive DAergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and FFA. Increase in IL-1β production following neuronal death possibly mediated this decrease.</abstract><cop>New York</cop><pub>Springer US</pub><doi>10.1007/s11011-021-00868-4</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-5825-8758</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0885-7490
ispartof Metabolic brain disease, 2022-02, Vol.37 (2), p.373-381
issn 0885-7490
1573-7365
language eng
recordid cdi_proquest_journals_2622096471
source Springer Nature - Complete Springer Journals
subjects Biochemistry
Biomedical and Life Sciences
Biomedicine
Metabolic Diseases
Neurology
Neurosciences
Oncology
Original Article
title RETRACTED ARTICLE: Chronic and progressive dopaminergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and free fatty acids, the role of interlokin-1 beta
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T06%3A54%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=RETRACTED%20ARTICLE:%20Chronic%20and%20progressive%20dopaminergic%20neuronal%20death%20in%20substantia%20nigra%20associates%20with%20a%20decrease%20in%20serum%20levels%20of%20glucose%20and%20free%20fatty%20acids,%20the%20role%20of%20interlokin-1%20beta&rft.jtitle=Metabolic%20brain%20disease&rft.au=Sarbazi-Golezari,%20Ali&rft.date=2022-02-01&rft.volume=37&rft.issue=2&rft.spage=373&rft.epage=381&rft.pages=373-381&rft.issn=0885-7490&rft.eissn=1573-7365&rft_id=info:doi/10.1007/s11011-021-00868-4&rft_dat=%3Cproquest_cross%3E2622096471%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2622096471&rft_id=info:pmid/&rfr_iscdi=true